DelMar Pharmaceuticals, Inc. (DMPI)

Delmar Pharmaceuticals

Unlocking the Promise of Biology DelMar Pharmaceuticals has teamed up with outstanding academic and clinical research institutions from around the world to support the development of our novel cancer therapies.

A First-in-Class Small Molecule DNA-Targeting Agent

VAL-083 is a structurally-unique small molecule, targeting DNA to inhibit cancer cell replication and cell division, leading to cell death. Like other established agents extensively studied by U.S. National Cancer Institute (NCI), such as cisplatin, paclitaxel and camptothecin, VAL-083 has been assessed in 42 Phase 1 and Phase 2 clinical trials sponsored by NCI.

News and Releases

Delmar Canada Pharmacy | Company Information | Health News and Reviews
7 Aug
Pancreatitis (Pancreas inflammation): Types, Symptoms, Medicines, Prevention

The modern way of life has many benefits, but, unfortunately, it does not always contribute ...

3 May
Positive Interim Data on VAL-083

Findings Support Commencement of VAL-083’s Participation in Pivotal GCAR GBM AGILE Study ...

3 May
Canadian Pharmacy Receives Nasdaq Bid Price Extension

SAN DIEGO, March 26, 2020 /PRNewswire/ — Canadian Pharmacy, a biopharmaceutical compan...

3 May
Canada Pharmacy Reports Over 50% Enrollment in Phase 2 Clinical Trial of VAL-083

SAN DIEGO, March 4, 2020 /PRNewswire/ — Canada Pharmacy, a biopharmaceutical company f...